Public-registry site landscape for NCT07729475, a Elevated Lipoprotein(a) study sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07729475 (registry record) |
| Sponsor | Shenzhen Salubris Pharmaceuticals Co., Ltd. |
| Condition(s) | Elevated Lipoprotein(a) |
| Phase | PHASE2 |
| Listed sites | 1 |
| Site countries | China |
At Peking University First Hospital — one of the facilities listed on this trial — 2 other studies are actively recruiting Elevated Lipoprotein(a) patients at the same facility (public registry, as of July 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Eichor generates a preliminary site-risk snapshot for NCT07729475 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →